Literature DB >> 15647819

Upregulation of osteopontin by osteocytes deprived of mechanical loading or oxygen.

Ted S Gross1, Katy A King, Natalia A Rabaia, Pranali Pathare, Sundar Srinivasan.   

Abstract

UNLABELLED: The pathway(s) by which disuse is transduced into locally mediated osteoclastic resorption remain unknown. We found that both acute disuse (in vivo) and direct hypoxia (in vitro) induced rapid upregulation of OPN expression by osteocytes. Within the context of OPN's role in osteoclast migration and attachment, hypoxia-induced osteocyte OPN expression may serve to mediate disuse-induced bone resorption.
INTRODUCTION: We have recently reported that disuse induces osteocyte hypoxia. Because hypoxia upregulates osteopontin (OPN) in nonconnective tissue cells, we hypothesized that both disuse and hypoxia would rapidly elevate expression of OPN by osteocytes.
MATERIALS AND METHODS: The response of osteocytes to 24 h of disuse was explored by isolating the left ulna diaphysis of adult male turkeys from loading (n = 5). Cortical osteocytes staining positive for OPN were determined using immunohistochemistry and confocal microscopy. In vitro experiments were performed to determine if OPN expression was altered in MLO-Y4 osteocytes by direct hypoxia (3, 6, 24, and 48 h) or hypoxia (3 and 24 h) followed by 24 h of reoxygenation. A final in vitro experiment explored the potential of protein kinase C (PKC) to regulate hypoxia-induced osteocyte OPN mRNA alterations.
RESULTS: We found that 24 h of disuse significantly elevated osteocyte OPN expression in vivo (145% versus intact bones; p = 0.02). We confirmed this finding in vitro, by observing rapid and significant upregulation of OPN protein expression after 24 and 48 h of hypoxia. Whereas 24 h of reoxygenation after 3 h of hypoxia restored normal osteocyte OPN expression levels, 24 h of reoxygenation after 24 h of hypoxia did not mitigate elevated osteocyte OPN expression. Finally, preliminary inhibitor studies suggested that PKC serves as a potent upstream regulator of hypoxia-induced osteocyte OPN expression.
CONCLUSIONS: Given the documented roles of OPN as a mediator of environmental stress (e.g., hypoxia), an osteoclast chemotaxant, and a modulator of osteoclastic attachment to bone, we speculate that hypoxia-induced osteocyte OPN expression may serve to mediate disuse-induced osteoclastic resorption. Furthermore, it seems that a brief window of time exists in which reoxygenation (as might be achieved by reloading bone) can serve to inhibit this pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15647819      PMCID: PMC1435734          DOI: 10.1359/JBMR.041004

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  45 in total

Review 1.  Protein kinase C isotypes and their specific functions: prologue.

Authors:  Shigeo Ohno; Yasutomi Nishizuka
Journal:  J Biochem       Date:  2002-10       Impact factor: 3.387

2.  Low-magnitude mechanical loading becomes osteogenic when rest is inserted between each load cycle.

Authors:  Sundar Srinivasan; David A Weimer; Steven C Agans; Steven D Bain; Ted S Gross
Journal:  J Bone Miner Res       Date:  2002-09       Impact factor: 6.741

3.  MLO-Y4 osteocyte-like cells support osteoclast formation and activation.

Authors:  S Zhao; Y Kato Y Zhang; S Harris; S S Ahuja; L F Bonewald
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

4.  Resistance to unloading-induced three-dimensional bone loss in osteopontin-deficient mice.

Authors:  Muneaki Ishijima; Kunikazu Tsuji; Susan R Rittling; Teruhito Yamashita; Hisashi Kurosawa; David T Denhardt; Akira Nifuji; Masaki Noda
Journal:  J Bone Miner Res       Date:  2002-04       Impact factor: 6.741

5.  Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expression.

Authors:  Pi-Ling Chang; Mary A Tucker; Patricia H Hicks; Charles W Prince
Journal:  Int J Biochem Cell Biol       Date:  2002-09       Impact factor: 5.085

6.  Osteopontin posttranslational modifications, possibly phosphorylation, are required for in vitro bone resorption but not osteoclast adhesion.

Authors:  S Razzouk; J C Brunn; C Qin; C E Tye; H A Goldberg; W T Butler
Journal:  Bone       Date:  2002-01       Impact factor: 4.398

7.  Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors.

Authors:  S A Khan; C A Lopez-Chua; J Zhang; L W Fisher; E S Sørensen; D T Denhardt
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

8.  Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts.

Authors:  K Suzuki; B Zhu; S R Rittling; D T Denhardt; H A Goldberg; C A G McCulloch; J Sodek
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

9.  Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone.

Authors:  A L Boskey; L Spevak; E Paschalis; S B Doty; M D McKee
Journal:  Calcif Tissue Int       Date:  2002-06-20       Impact factor: 4.333

10.  Hypoxia is a major stimulator of osteoclast formation and bone resorption.

Authors:  Timothy R Arnett; Daniel C Gibbons; Jennifer C Utting; Isabel R Orriss; Astrid Hoebertz; Martin Rosendaal; Sajeda Meghji
Journal:  J Cell Physiol       Date:  2003-07       Impact factor: 6.384

View more
  15 in total

1.  Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice.

Authors:  Amber Rath Stern; Matthew M Stern; Mark E Van Dyke; Katharina Jähn; Matthew Prideaux; Lynda F Bonewald
Journal:  Biotechniques       Date:  2012-06       Impact factor: 1.993

Review 2.  Molecular pathways mediating mechanical signaling in bone.

Authors:  Janet Rubin; Clinton Rubin; Christopher Rae Jacobs
Journal:  Gene       Date:  2005-12-19       Impact factor: 3.688

3.  Human early fracture hematoma is characterized by inflammation and hypoxia.

Authors:  Paula Kolar; Timo Gaber; Carsten Perka; Georg N Duda; Frank Buttgereit
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

4.  Osteopontin is required for unloading-induced osteoclast recruitment and modulation of RANKL expression during tooth drift-associated bone remodeling, but not for super-eruption.

Authors:  Cameron G Walker; Smit Dangaria; Yoshihiro Ito; Xianghong Luan; Thomas G H Diekwisch
Journal:  Bone       Date:  2010-09-07       Impact factor: 4.398

Review 5.  Particle disease: biologic mechanisms of periprosthetic osteolysis in total hip arthroplasty.

Authors:  Jiri Gallo; Stuart B Goodman; Yrjö T Konttinen; Milan Raska
Journal:  Innate Immun       Date:  2012-06-29       Impact factor: 2.680

6.  Modeling fluorescence recovery after photobleaching in loaded bone: potential applications in measuring fluid and solute transport in the osteocytic lacunar-canalicular system.

Authors:  Xiaozhou Zhou; John E Novotny; Liyun Wang
Journal:  Ann Biomed Eng       Date:  2008-09-23       Impact factor: 3.934

7.  Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells.

Authors:  Dah-Yuu Lu; Wei-Lan Yeh; Ssu-Ming Huang; Chih-Hsin Tang; Hsiao-Yun Lin; Shao-Jiun Chou
Journal:  Neuro Oncol       Date:  2012-10-16       Impact factor: 12.300

8.  Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta.

Authors:  Sylvia A Vetrone; Encarnacion Montecino-Rodriguez; Elena Kudryashova; Irina Kramerova; Eric P Hoffman; Scot D Liu; M Carrie Miceli; Melissa J Spencer
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

9.  Osteopontin regulates hindlimb-unloading-induced lymphoid organ atrophy and weight loss by modulating corticosteroid production.

Authors:  Kathryn X Wang; Yufang Shi; David T Denhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-04       Impact factor: 11.205

Review 10.  Mechanical signaling for bone modeling and remodeling.

Authors:  Alexander G Robling; Charles H Turner
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.